Molecular Oncology
Volume 2, Issue 3 , Pages 233-240 , October 2008

TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles

  • Hanne Offenberg

      Affiliations

    • Department of Veterinary Pathobiology, Section of Biomedicine, Faculty of Life Sciences, University of Copenhagen, DK-1870 Frederiksberg C, Denmark
    • ,
  • Nils Brünner

      Affiliations

    • Department of Veterinary Pathobiology, Section of Biomedicine, Faculty of Life Sciences, University of Copenhagen, DK-1870 Frederiksberg C, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 26 14 47 08.
    • ,
  • Francisco Mansilla

      Affiliations

    • Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital/Skejby, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark
    • ,
  • F. Ørntoft Torben

      Affiliations

    • Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital/Skejby, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark
    • ,
  • Karin Birkenkamp-Demtroder

      Affiliations

    • Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital/Skejby, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark

Received 29 February 2008 ,Revised 6 June 2008 ,Accepted 10 June 2008.

References 

  1. Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Experimental Cell Research. 2004;301:158–167
  2. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. British Journal of Surgery. 2000;87:1215–1221
  3. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, et al. Gene expression in colorectal cancer. Cancer Research. 2002;62:4352–4363
  4. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut. 2005;54:374–384
  5. Birkenkamp-Demtroder K, Mansilla F, Sørensen FB, Kruhøffer M, Christensen L, Aaltonen LA, et al. Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Molecular Oncology. 2007;1:181–195
  6. Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, et al. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Digestive Diseases and Sciences. 2004;49:653–661
  7. Daniel P, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska O, Malecka-Panas E. Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. International Journal of Colorectal Disease. 2007;22:1165–1172
  8. Davidsen ML, Wurtz SO, Romer MU, Sorensen NM, Johansen SK, Christensen IJ, et al. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. British Journal of Cancer. 2006;95:1114–1120
  9. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. International Journal of Cancer. 2001;93:204–211
  10. Fong SF, Dietzsch E, Fong KS, Hollosi P, Asuncion L, He Q, et al. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumours and associated with less differentiated colon tumours. Genes Chromosomes Cancer. 2007;46:644–655
  11. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B Cells. Blood. 1998;92:1342–1349
  12. Guillem JG, Levy MF, Hsieh LL, Johnson MD, LoGerfo P, Forde KA, et al. Increased levels of phorbin, c-myc, and ornithine decarboxylase RNAs in human colon cancer. Molecular Carcinogenesis. 1990;3:68–74
  13. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clinical Cancer Research. 2000;6:4292–4299
  14. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clinical Cancer Research. 2002;8:156–164
  15. Holten-Andersen MN, Hansen U, Brunner N, Nielsen HJ, Illemann M, Nielsen BS. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. International Journal of Cancer. 2005;113:198–206
  16. Jung KK, Liu XW, Chirco R, Fridman R, Kim HRC. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO Journal. 2006;25:3934–3942
  17. Kruhoffer M, Jensen JL, Laiho P, Dyrskjot L, Salovaara R, Arango D, et al. Gene expression signatures for colorectal cancer microsatellite status and HNPCC. British Journal of Cancer. 2005;92:2240–2248
  18. Liu XW, Bernardo MM, Fridman R, Kim HRC. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. Journal of Biological Chemistry. 2003;278:40364–40372
  19. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: A potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Research. 2005;65:898–906
  20. Mansilla F, Birkenkamp-Demtroder K, Kruhoffer M, Sorensen FB, Andersen CL, Laiho P, et al. Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups. British Journal of Cancer. 2007;96:1896–1903
  21. Matsushita M, Matsuzaki K, Date M, Watanabe T, Shibano K, Nakagawa T, et al. Down regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. British Journal of Cancer. 1999;80:194–205
  22. Nagase H, Woessner JF. Matrix metalloproteinases. Journal of Biological Chemistry. 1999;274:21491–21494
  23. Peinado H, del Carmen M, de la Cruz I, Olmeda D, Csiszar K, Fong KSK, et al. A molecular role for lysyl oxidase-like 2 enzyme in Snail regulation and tumour progression. EMBO Journal. 2005;24:3446–3458
  24. Powe DG, Brough JL, Carter GI, Bailey EM, StetlerStevenson WG, Turner DR, et al. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. British Journal of Cancer. 1997;75:1678–1683
  25. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. Tumour tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clinical Cancer Research. 2004;10:2289–2298
  26. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, et al. Primary tumour levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clinical Cancer Research. 2006;12:7054–7058
  27. Sieuwerts AM, Klijn JGM, Henzen-Logmans SC, Bouwman I, Van Roozendaal KEP, Peters HA, et al. Urokinase-type-plasminogen-activator (uPA) production by human breast (myo)fibroblasts in vitro: Influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells. International Journal of Cancer. 1998;76:829–835
  28. Sorensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ, Brunner N, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clinical Cancer Research. 2007;13:4117–4122
  29. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. Transforming growth factor-beta 1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. Journal of Biological Chemistry. 2004;279:8567–8576
  30. Westbrook CA, Gasson JC, Gerber SE, Selsted ME, Golde DW. Purification and characterization of human T-lymphocyte-derived erythroid-potentiating activity. Journal of Biological Chemistry. 1984;259:9992–9996
  31. Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, Korc M. Overexpression of activin A in stage IV colorectal cancer. Gut. 2001;49:409–417
  32. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer and Metastasis Reviews. 2004;23:101–117

PII: S1574-7891(08)00073-2

doi: 10.1016/j.molonc.2008.06.003

Molecular Oncology
Volume 2, Issue 3 , Pages 233-240 , October 2008

Article Tools

* Image Usage & Resolution